High CEACAM6 expression was associated with breast cancer recurrence following adjuvant tamoxifen, and knockdown of CEACAM6 restored tamoxifen sensitivity and reduced clonogenic growth, migration, and invasion of tamoxifen-resistant MCF-7 cells [36, 37]. Here, CEACAM6 is linked to breast carcinoma.